1. Home
  2. SACH vs ICCM Comparison

SACH vs ICCM Comparison

Compare SACH & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.04

Market Cap

47.5M

Sector

Real Estate

ML Signal

HOLD

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.70

Market Cap

43.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
ICCM
Founded
2010
2006
Country
United States
Israel
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
47.5M
43.4M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SACH
ICCM
Price
$1.04
$0.70
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$2.00
$2.50
AVG Volume (30 Days)
266.6K
382.4K
Earning Date
11-05-2025
11-19-2025
Dividend Yield
19.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,906,000.00
$2,975,000.00
Revenue This Year
N/A
$13.67
Revenue Next Year
$1.73
$38.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.58
52 Week High
$1.35
$1.66

Technical Indicators

Market Signals
Indicator
SACH
ICCM
Relative Strength Index (RSI) 48.04 57.06
Support Level $1.01 $0.58
Resistance Level $1.08 $0.68
Average True Range (ATR) 0.04 0.03
MACD 0.00 0.01
Stochastic Oscillator 32.09 98.44

Price Performance

Historical Comparison
SACH
ICCM

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: